Cargando…

COX-2 Overexpression in Schneiderian Papillomas

BACKGROUND: Schneiderian papillomas (SP) are aggressive sinonasal tumors that occasionally extend into areas that are surgically unresectable. OBJECTIVE: evaluate the signifcance of cyclo-oxygenase-2 (COX-2) expression in SP. METHODS: Immunohistochemistry for COX-2 was performed on SP samples and mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Suh, Jeffrey D., Hur, Kevin, Ference, Elisabeth H., Lam, David D., Fong, Andrew, Correa, Adrian J., Wrobel, Bozena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731694/
https://www.ncbi.nlm.nih.gov/pubmed/33343991
http://dx.doi.org/10.1177/2152656720973689
_version_ 1783621950746132480
author Suh, Jeffrey D.
Hur, Kevin
Ference, Elisabeth H.
Lam, David D.
Fong, Andrew
Correa, Adrian J.
Wrobel, Bozena
author_facet Suh, Jeffrey D.
Hur, Kevin
Ference, Elisabeth H.
Lam, David D.
Fong, Andrew
Correa, Adrian J.
Wrobel, Bozena
author_sort Suh, Jeffrey D.
collection PubMed
description BACKGROUND: Schneiderian papillomas (SP) are aggressive sinonasal tumors that occasionally extend into areas that are surgically unresectable. OBJECTIVE: evaluate the signifcance of cyclo-oxygenase-2 (COX-2) expression in SP. METHODS: Immunohistochemistry for COX-2 was performed on SP samples and middle turbinates from chronic rhinosinusitis without nasal polyps controls obtained during surgical resection between 2009–2017. A positive stain was defined as having 10% or more cells exhibiting diffuse immunoreactivity. Comparisons were performed using Fisher Exact tests, t-tests, and ANOVA. RESULTS: The study included 67 tumor samples and 9 controls from two academic institutions. The mean age of the SP group was 55.4 years and 53.2 years in the control group (p = 0.71). Thirty-nine (58.2%) SP patients had previous surgery compared to 1 (11.1%) in the control group (p = 0.01). The most common tumor attachment sites were the maxillary (47.8%) and ethmoid (25.4%) sinuses. Fifteen (22.4%) SP samples stained strongly positive for COX-2 and 24 (35.8%) stained weakly positive compared to no positive stains in the control group (p < 0.01). When stratified by COX-2 intensity, there were no statistically significant differences in gender, smoking history, history of previous sinus surgery, site of attachment, papilloma subtype, or future recurrence between SP samples. CONCLUSION: COX-2 was overexpressed in 58.2% of SP cases, and strongly positive in 22.4% of cases, compared to no positive staining among controls. No significant differences in COX-2 expression were observed between SP subtypes or recurrent tumors. Further studies are warranted to evaluate COX-2 as a possible therapeutic target in tumors that overexpress the enzyme.
format Online
Article
Text
id pubmed-7731694
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77316942020-12-18 COX-2 Overexpression in Schneiderian Papillomas Suh, Jeffrey D. Hur, Kevin Ference, Elisabeth H. Lam, David D. Fong, Andrew Correa, Adrian J. Wrobel, Bozena Allergy Rhinol (Providence) Original Article BACKGROUND: Schneiderian papillomas (SP) are aggressive sinonasal tumors that occasionally extend into areas that are surgically unresectable. OBJECTIVE: evaluate the signifcance of cyclo-oxygenase-2 (COX-2) expression in SP. METHODS: Immunohistochemistry for COX-2 was performed on SP samples and middle turbinates from chronic rhinosinusitis without nasal polyps controls obtained during surgical resection between 2009–2017. A positive stain was defined as having 10% or more cells exhibiting diffuse immunoreactivity. Comparisons were performed using Fisher Exact tests, t-tests, and ANOVA. RESULTS: The study included 67 tumor samples and 9 controls from two academic institutions. The mean age of the SP group was 55.4 years and 53.2 years in the control group (p = 0.71). Thirty-nine (58.2%) SP patients had previous surgery compared to 1 (11.1%) in the control group (p = 0.01). The most common tumor attachment sites were the maxillary (47.8%) and ethmoid (25.4%) sinuses. Fifteen (22.4%) SP samples stained strongly positive for COX-2 and 24 (35.8%) stained weakly positive compared to no positive stains in the control group (p < 0.01). When stratified by COX-2 intensity, there were no statistically significant differences in gender, smoking history, history of previous sinus surgery, site of attachment, papilloma subtype, or future recurrence between SP samples. CONCLUSION: COX-2 was overexpressed in 58.2% of SP cases, and strongly positive in 22.4% of cases, compared to no positive staining among controls. No significant differences in COX-2 expression were observed between SP subtypes or recurrent tumors. Further studies are warranted to evaluate COX-2 as a possible therapeutic target in tumors that overexpress the enzyme. SAGE Publications 2020-12-08 /pmc/articles/PMC7731694/ /pubmed/33343991 http://dx.doi.org/10.1177/2152656720973689 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Suh, Jeffrey D.
Hur, Kevin
Ference, Elisabeth H.
Lam, David D.
Fong, Andrew
Correa, Adrian J.
Wrobel, Bozena
COX-2 Overexpression in Schneiderian Papillomas
title COX-2 Overexpression in Schneiderian Papillomas
title_full COX-2 Overexpression in Schneiderian Papillomas
title_fullStr COX-2 Overexpression in Schneiderian Papillomas
title_full_unstemmed COX-2 Overexpression in Schneiderian Papillomas
title_short COX-2 Overexpression in Schneiderian Papillomas
title_sort cox-2 overexpression in schneiderian papillomas
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731694/
https://www.ncbi.nlm.nih.gov/pubmed/33343991
http://dx.doi.org/10.1177/2152656720973689
work_keys_str_mv AT suhjeffreyd cox2overexpressioninschneiderianpapillomas
AT hurkevin cox2overexpressioninschneiderianpapillomas
AT ferenceelisabethh cox2overexpressioninschneiderianpapillomas
AT lamdavidd cox2overexpressioninschneiderianpapillomas
AT fongandrew cox2overexpressioninschneiderianpapillomas
AT correaadrianj cox2overexpressioninschneiderianpapillomas
AT wrobelbozena cox2overexpressioninschneiderianpapillomas